Methimazole-induced cholestatic hepatitis: two cases report and literature review

Methimazole is commonly prescribed for patients who are thyrotoxic. Cholestatic hepatitis is a rare but serious adverse event which may be associated with interventional therapy. In this case report, we present two Chinese women with cholestatic jaundice due to methimazole treatment. Both patients h...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-01, Vol.7 (4), p.5088-5091
Main Authors: Zou, Hai, Jin, Lie, Wang, Li-Ren, Braddock, Martin, Cai, Wen-Wei, Zheng, Ming-Hua
Format: Article
Language:English
Subjects:
Adult
Anti-Inflammatory Agents - therapeutic use
Antithyroid Agents - adverse effects
Case Report
Drug-Related Side Effects and Adverse Reactions
Female
Hepatitis - drug therapy
Hepatitis - etiology
Humans
Hyperthyroidism - drug therapy
Jaundice, Obstructive - chemically induced
Jaundice, Obstructive - drug therapy
Methimazole - adverse effects
Methylprednisolone - therapeutic use
Middle Aged
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methimazole is commonly prescribed for patients who are thyrotoxic. Cholestatic hepatitis is a rare but serious adverse event which may be associated with interventional therapy. In this case report, we present two Chinese women with cholestatic jaundice due to methimazole treatment. Both patients had a history of hyperthyroidism; initial laboratory studies of liver function were normal and cholestatic hepatitis occurred after treatment with methimazole. Concomitant liver disease, such as viral hepatitis (A, B, C, D, E), autoimmune hepatitis, primary biliary cirrhosis and calculus of bile duct, were excluded. Liver enzyme levels in both patients returned to normal after stopping methimazole therapy and taking hepatoprotective drugs. It is essential that patients are informed about the earliest symptoms of serious adverse effects of antithyroid drugs, such as hepatic toxicity, and that they are advised to stop taking the drug immediately and contact their physician if such symptoms occur.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.6144